The evaluation of anti-CD70 monotherapy in combination with anti-PD-1 therapy using xenograft-derived organoids and humanized mice showed improved tumor-killing efficacy.446 Additionally, a recent study reported that PD-1 + IL-2 combination therapy significantly alters the differentiation program of PD-1 + TCF-1+ stem-like CD8 + T cells, which merits consideration as a potential regimen for cancer treatment.447 Also, clinical trials of combination ICIs have achieved significant results, and more clinical trials are underway. The gene discussed is CD70; the disease is neoplasm.